New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Accessibility StatementSkip Navigation PALO ALTO, Calif., Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today new data from the APEX study of KSI-101 presented at the Retina Society 58 Annual Scientific Meeting in Chicago, Illinois. Continue Reading Proportion of patients with macular edema secondary to inflammation (MESI) achieving absence ...